Preventative ibandronate treatment has the most benefi cial effect on the microstructure of bone in experimental tumor osteolysis Abstract We investigated the effect of ibandronate on three-dimensional (3-D) microstructure and bone mass in experimentally induced tumor osteolysis. Walker carcinosarcoma cells were implanted into the left femur of female rats that received 26-day ibandronate pretreatment followed by continued therapy or ibandronate posttreatment only. A tumor-only group received isotonic saline. At endpoint, excised femurs were scanned using microcomputed tomography (µCT) to assess bone volume density, bone mineral content, trabecular number/thickness, and separation for cortical plus trabecular bone or trabecular bone alone. Compared with the nonimplanted right femur, bone volume and surface density and trabecular number and thickness were reduced in the distal left femur following tumor cell implantation. µCT analysis revealed greater cortical and trabecular bone mineral content in the preventative and interventional (pre-post tumor) ibandronate group, and the interventional (post-tumor) ibandronate group, versus the tumor-only group. Bone volume density was signifi cantly higher in pre-post and post-tumor groups compared to the tumor-only group. After preventative and interventional ibandronate, bone volume density and trabecular thickness were 13% and 60% greater, respectively, than in the post-tumor treatment group. 3-D µCT images confi rmed microstructural changes. We conclude that combined interventional and preventative ibandronate preserves bone strength and integrity more than intervention alone.
Introduction
Skeletal metastases are the most frequent complication of malignant tumors and are associated with severe pain and pathological fractures. Although treatment for metastatic bone lesions does not alter life expectancy, preventing fractures can improve the quality of life of the cancer patient. Bisphosphonates are one class of therapeutic agents currently being used or under investigation for various diseases related to pathologically increased bone resorption, such as Paget's disease, postmenopausal osteoporosis, and tumor-induced hypercalcemia and osteolysis [1] . Over recent years, bisphosphonates have also become an established treatment for bone metastases, and are currently the only available treatment option for bone complications associated with malignancies. Bisphosphonates are able to reduce the number of skeletal complications by inhibiting osteoclast-mediated bone destruction. Numerous experimental and clinical studies have shown that interventional treatment can reduce the occurrence of pathological fractures, bone pain, hypercalcemia, and the need for radiotherapy and surgery [2] .
Preclinical studies and initial clinical experience show that preventative administration of bisphosphonates seems very promising and more benefi cial for the patient than palliative administration alone [3] [4] [5] [6] [7] [8] [9] . Investigations into the use of bisphosphonates are now directed to understand the effects of a preventative treatment on tumor osteolysis [10] . A recent investigation on bone quality in tumor osteolysis showed that tumor growth in bone resulted in a decrease in bone mass and the loss of biomechanical competence of bone, but they are not correlated [11] . In addition, new imaging techniques for determining the alteration of the three-dimensional (3-D) structure of trabecular bone, a factor known to infl uence its mechanical behavior, have been introduced [12] .
We utilized this new technology in a previous study and demonstrated that microcomputed tomography (µCT) can provide 3-D parameters of bone mass and trabecular structure in an animal model for tumor-induced bone loss [13] . We found signifi cant differences in 3-D morphometric parameters between the tumor-bearing bones and contralateral controls.
In the current experimental study, we investigated the effect of a preventative administration of ibandronate on the 3-D microstructure of bone in a rat model for tumorinduced osteolysis. Building on previously published experiments [11, [13] [14] [15] , this study aimed to investigate whether interventional treatment with ibandronate affects the tumor-induced destruction of the 3-D structure of trabecular bone, and whether preventative treatment combined with interventional treatment preserves the 3-D structure of trabecular bone in tumor osteolysis better than interventional treatment alone.
Materials and methods

Animal model and treatment protocol
We used a previously described animal model to evaluate densitometric and biomechanical properties in tumor osteolysis [11, [13] [14] [15] . The widely used Walker Carcinosarcoma 256 malignant breast cancer cells (W256) were cultured in 0.6% agarose gel solution. After anesthesia by an intraperitoneal injection of ketamine hydrochloride (75 mg/kg) and xylazine (5 mg/kg), equivalent volumes of tumor cells in agarose gel containing approximately 2 × 10 6 cells were surgically implanted into the medullary canal of the left femur via a drill hole in the intercondylar notch (see [15] for additional details). Forty-fi ve female Sprague-Dawley rats aged 4 months were randomly assigned to three study groups. All animals were maintained in accordance with federal regulations, and the study was conducted with the approval of the Institutional Animal Care and Use Committee (Harvard Medical School). In the fi rst group (tumor-only), Walker 256 tumor cells were implanted into the left femur without treatment. The second group (prepost) fi rst underwent a daily pretreatment with ibandronate (Roche Diagnostics, Mannheim, Germany; 25 µg/kg subcutaneously) for 26 days; then, tumor cells were implanted and the daily treatment was continued until death. The third group (post) received daily ibandronate treatment only after tumor cell implantation. There were no complications from the surgical procedure. Twenty-eight days after surgery, all animals were killed and both femora from each rat were harvested and cleaned of soft tissue for image analysis. Before microtomographic scanning, all femora were radiographed in an anteroposterior plane using a Faxitron machine (Hewlett-Packard, McMinnville, OR, USA).
Structural analysis using microcomputed tomography (µCT) As in our recent study [13] , we employed a desktop µCT imaging system (µCT 20; Scanco Medical, Bassersdorf, Switzerland: 30 µm, nominal resolution) to assess 3-D densitometric and architectural parameters in small animal whole bones. The µCT system has a micro-X-ray source (10 µm focal spot, 25 keV) directed toward the sample. The quantitative modifi cation of the X-ray beam by apatite crystals contained in the bone sample is analyzed by a plane detector (CCD array; 1024 elements). The process is piloted by an Alpha workstation (HP, Palo Alto, CA, USA) and an OpenVMS system in cluster confi guration to perform the 3-D analysis. For each specimen, a total of 200 microtomographic slices were taken, each 30 µm thick, starting from a reproducible anatomical landmark right behind the boundary of the condyles, thereby covering a 6-mm region of the distal femur. From the obtained twodimensional slices, 3-D reconstruction of bone was automatically performed using the triangulation algorithm. Architectural indices were calculated in the spherical volume of interest according to standard defi nitions used in histomorphometry [11] . Bone volume density (bone volume/tissue volume), bone surface density (bone surface/ bone volume), trabecular thickness, trabecular separation, and trabecular number were determined directly from the 3-D images. Bone mineral content, calculated using the measured bone volume and assuming a constant tissue density, was measured in a metaphyseal region consisting of both cortical and trabecular bone, and a sphere consisting of trabecular bone only. In a previous study, calculations of bone mineral content using this method were shown to correlate closely to dual-energy X-ray absorptiometry (DXA)-based methods [16] , and in a separate study, the bone volume densities of metastatic cancer bone and normal bone were found to be similar [17] . A total of 90 specimens (left and right femora) were scanned. All 90 specimens were analyzed using both visual assessment and quantitative morphometry.
Statistical analysis
A Wilk-Shapiro test for normality was conducted on all parameters. All data were expressed as the mean ± standard deviation. Analysis of variance (ANOVA) with Student-Newman-Keuls post hoc analysis, or a paired t test was performed to determine if the measurements differed signifi cantly (statistical signifi cance level, P < 0.05).
Results
This model of tumor induction in bone has been characterized previously [11, [13] [14] [15] . As with previous studies, radiographs confi rmed that all femora implanted with tumor cells contained osteolytic lesions [11, 15] . In addition, there was macroscopic evidence of soft tissue tumors surrounding affected bones.
Compared with the nonimplanted right femur, bone volume density, bone surface density, trabecular number, and trabecular thickness were signifi cantly reduced in the distal left femur following the implantation of tumor cells (P < 0.001). Trabecular separation was signifi cantly increased in the left femur ( Table 1) .
The µCT analysis revealed greater values for cortical and trabecular bone mineral content in the preventative and interventional (pre-post tumor) ibandronate treatment group, and the interventional (post-tumor) ibandronate treatment group, than in the tumor-only group (Table 2) . Morphometric analysis of trabecular volume revealed architectural changes in accordance with the quantitative changes seen in bone density (Figs. 1-4) .
Changes in architectural parameters of the left femur following treatment with ibandronate are summarized in Table 3 . Bone volume density was signifi cantly higher in the pre-post and post-tumor groups compared to the tumor-only group, showing an increase of 133% and 106%, respectively (P < 0.05) ( Table 3) . These results are most likely caused by a signifi cant increase in trabecular thickness (up by 211% and 95% versus the tumor-only group, respectively; P < 0.05) ( Table 3 ). In addition, trabecular separation signifi cantly decreased in the pre-post (−74%) and post-tumor (−73%) treatment groups (P < 0.05 versus tumor only) ( Table 3) . Values recorded in the pre-post ibandronate treatment group were 13% greater for bone volume density and 60% greater for trabecular thickness than in the post-tumor treatment group (P < 0.05) ( Table 3) . Bone surface density and trabecular number were not affected by ibandronate treatment (see Table 3 ).
Discussion
The aim of the present study was to investigate the effect of a bisphosphonate, ibandronate, on bone density and 3-D bone structure in a rat model of tumor-induced osteolysis. Previously, we presented biomechanical and mineralization data with this model and treatment regimen, including DXA-based measurements, and also demonstrated no effects on serum calcium with the ibandronate doses used [11] . Other studies have also demonstrated that ibandronate does not induce either hypomineralization or hypermineralization, even at doses exceeding any therapeutically intended dose by multiples [11, 18, 19] .
From clinical experience, it is known that bone metastases frequently occur in the metaphyseal regions of long bones and the vertebral bodies of the spine. In those areas, the turnover rate of trabecular bone is much greater than that of cortical bone; consequently, dramatic changes in tumor osteolysis occur in trabecular bone much later than in cortical bone. This also is the region of bone where the effect of an interventional treatment with bisphosphonates is more pronounced [20, 21] . In recent years, 3-D analysis of bone has become possible using µCT technology. This tool rapidly evaluates the internal morphology and structure of trabecular and cortical bone, and has been widely used in osteoporosis research and to examine the effects of pharmacological intervention on bone [12, [22] [23] [24] [25] [26] [27] . In particular, µCT imaging allows the noninvasive examination of the quantity, orientation, and connection of trabecular bone elements separately from cortical bone by focusing on a selected volume of interest containing trabecular bone only.
The results of the present study confi rm that ibandronate administered either as a daily interventional treatment starting after the onset of tumor growth in bone, or as both a preventative and interventional treatment, preserves bone mass and 3-D structure compared with an untreated tumor-only control group. However, we found a greater benefi cial effect on density, mineral content, and trabecular thickness in the preventative and interventional ibandronate group than the intervention-only group. In a previous study, we found that preventative and interventional treatment increased failure load by 9% versus interventional treatment alone in this model, although this was not statistically signifi cant [11] . These data may suggest a potential for preventative ibandronate treatment to reduce the risk of fractures for patients. The similar number of trabeculae in the treatment groups indicates that ibandronate affected mostly existing trabeculae (i.e., increasing their width) rather than inducing formation of new trabeculae. These results are corroborated by two recent in vivo studies of bisphosphonate action on trabecular microarchitecture: a macaque study of preventative ibandronate for ovariectomy-induced bone loss in the lumbar spine [16] , and a human trial of risedronate for preserving iliac bone architecture in postmenopausal women with osteoporosis [28] . In both studies, trabecular number was preserved and trabecular thickness was increased in treatment groups compared with controls or baseline values.
Several studies in different experimental models have shown that preventative bisphosphonate treatment reduces the development of bone metastases. Preventative etidronate treatment reduced osteolysis and prolonged survival in a rat model of bone metastasis using bladder carcinoma cells [29] . In other studies using parathyroid hormonerelated protein-producing Walker 256 carcinosarcoma cells inoculated intraosseously into rats, pretreatment with clodronate or pamidronate was osteoprotective, with the extent of the effect correlating with duration and intensity of treatment [7] [8] [9] 30] . Preventative treatment with pamidronate was also shown to increase trabecular volume, although an increase in skeletal tumor burden was observed, with no effects on nonosseous metastases [6] . However, other studies of human breast carcinoma cells injected into nude mice have shown a reduced tumor burden following pretreatment with ibandronate [31] or risedronate [32] . In addition, in a similar rat model, risedronate pretreatment decreased the incidence of bone metastases with no effect on visceral metastases [4] . Previous studies performed in our laboratory showed that combined preventative and interventional treatment with ibandronate most effectively preserved bone mass and strength, although all ibandronate treatment schedules resulted in signifi cant improvements compared with untreated tumor-bearing controls [11, 14] . Supporting these results, a recent study of experimentally induced multiple tumor osteolysis in rats found that initiation of ibandronate therapy 3 days before tumor cell inoculation substantially reduced the development of osteolytic lesions compared with postoperative ibandronate administration [33] .
Our study did not investigate the mechanism of action for the observed benefi ts of preventative ibandronate treatment. Bisphosphonates have several potential inhibitory effects on bone metastases. In particular, these agents have a well-documented inhibitory effect on osteoclast function. Studies have shown that bisphosphonates induce apoptosis in murine osteoclasts both in vivo and in vitro, and a greater effect is seen with more potent agents [34, 35] . In addition, bisphosphonates may promote the secretion of an osteoclast inhibitory factor by osteoblasts [36] . Bisphosphonates also induce apoptosis in macrophages [37, 38] and human myeloma cell lines [39] in vitro. Other biological effects include inhibiting the adhesion of breast or prostate carcinoma cells to bone matrices [40, 41] , inhibiting matrix metalloproteinases in vitro and in vivo, and decreasing the invasive properties of malignant melanoma and fi brosarcoma cell lines [31, 42] .
In a previous study from our laboratory, we assessed the effects of preventative and interventional ibandronate treatment on nonimplanted femora [11] . As is well established, ibandronate increased various bone parameters (such as bone mineral density) in femora without tumors; however, the effects were less than those observed in tumor-implanted femora. Although this confi rms that ibandronate has additional effects on tumor-containing bone, it is unclear whether this is a result of timing of treatment or total dose administered. Regardless of mechanism, the present study further demonstrates that combined preventative and interventional ibandronate treatment is most benefi cial in our model, and this fi nding has direct relevance to clinical dosing.
Conclusions
In our animal model investigating the structural consequences of tumor destruction in trabecular bone, both ibandronate treatment schedules resulted in signifi cantly greater bone mass and improved structural parameters compared with no treatment. Combined preventative and continued treatment provided the best protection against tumor-mediated bone destruction and preserved the integrity of bone, even in the presence of a malignant tumor. Our experimentally obtained results for bone structure are in concordance with accumulating clinical evidence suggesting that preventative treatment with bisphosphonates can reduce the occurrence of skeletal complications in cancer patients and thus may prolong survival [43, 44] . These animal experiments and the current clinical experience with bisphosphonates suggest that further investigations that focus on preventative treatment are likely to be very promising.
